CC arrived at its Q1 2026 earnings release riding a 30% one-month rally — and then promptly fell back as the results hit the tape.
The week captured a classic pre-earnings long squeeze in reverse. The stock closed at $27.94 on May 5, up 8.7% on the week and nearly 30% higher than where it traded a month ago. Options traders had been leaning hard into the rally: the put/call ratio dropped to 0.25, well below its 20-day average of 0.30 and near the 52-week low of 0.21. Calls dominated flow for weeks running into the print, suggesting the move higher was partly options-driven. Then Q1 results crossed after the bell on May 5 and the stock gapped down, with headlines characterising the reaction as an "earnings shock." The setup going in was bullish; the outcome was not.
Short sellers were quietly unwinding as the stock ran. Short interest fell about 13% over the past month to 6.0% of the free float — still a meaningful position, but the direction of travel is clearly lower. The borrow market tells the same story: cost to borrow is running at just 0.42%, barely above its 30-day average and far from any stress level. Availability is loose — lending demand is minimal relative to the overall pool — and the ORTEX short score has drifted down from 43 in late April to 40.7, ranking in the 23rd percentile of the universe. Shorts were not the driver of this week's move, and they are not obviously positioned for a reversal either.
The Street was broadly constructive going into the quarter. Truist raised its target to $30 on April 28, keeping its Buy rating. UBS had lifted its target to $29 in early April. The current mean price target across the analyst panel is around $23 — notably below the $27.94 close, a gap worth flagging as a potential ceiling if the post-earnings gap down holds. Goldman Sachs and JP Morgan both carry Neutral ratings and have the most conservative targets, while the Buy-rated contingent at Truist and UBS appeared to be setting up for a positive earnings catalyst that did not materialise. The EPS surprise factor score ranks in the 94th percentile historically, meaning the company has typically beaten estimates comfortably — which may partly explain why expectations ran ahead of the result. The PE multiple has expanded about 3.3 turns over the past 30 days to 16.4x, and price-to-book climbed 1.6 turns to 8.5x. Both multiples contracted sharply in the post-close session.
The bull case centres on pricing power in Opteon HFO refrigerants and the "Pathway to Thrive" cost programme, which targets over $250 million in run-rate savings through 2027. The bear case focuses on slowing HFC/HFO demand from regulatory transitions, new TiO2 capacity that threatens margin recovery, and broader macro softness hitting housing and automotive end markets — the key sources of TiO2 volume. The Q1 print appears to have handed the bears at least a temporary point. A Q2 dividend of $0.09 was declared alongside results, a reduction from the $0.25 quarterly levels seen in 2021-2022, underscoring the financial repositioning still under way.
Closest peer TROX gained 4.8% on the day and 7% on the week, while KRO rose 5.1% and 8.2% — both TiO2 plays that moved broadly in line with CC's pre-earnings run. If the post-earnings gap holds into the open, the divergence between CC and its TiO2 peers will be the key spread to watch: whether the market reads the Q1 miss as Chemours-specific or as a warning for the segment.
What to watch next: how the stock digests the post-earnings gap relative to the analyst target cluster near $23, and whether short interest — which has been steadily unwinding — begins rebuilding now that the bullish catalyst has passed.
See the live data behind this article on ORTEX.
Open CC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
